Poor drug distribution as a possible explanation for the results of the PRECISE trial. - Wikidata - awgldk - TriplyDB

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

http://www.wikidata.org/entity/Q48374857

about

Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics Biomarkers for glioma immunotherapy: the next generation Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy Novel delivery strategies for glioblastoma Novel strategies in glioblastoma surgery aim at safe, supra-maximum resection in conjunction with local therapies Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.Rapid inverse planning for pressure-driven drug infusions in the brain Automated segmentation tool for brain infusions Influence of neuropathology on convection-enhanced delivery in the rat hippocampus Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics Therapeutic strategies to improve drug delivery across the blood-brain barrier.Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study Time-reversal acoustics and ultrasound-assisted convection-enhanced drug delivery to the brain.Targeted drug delivery across the blood-brain barrier using ultrasound technique.Neurosurgical oncology: advances in operative technologies and adjuncts.Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside.Neural stem cell therapy for cancer.An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.Imaging of convection enhanced delivery of toxins in humans.Experimental approaches for the treatment of malignant gliomas.Intracranial hyperthermia through local photothermal heating with a fiberoptic microneedle device.Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma Fiberoptic microneedle device facilitates volumetric infusate dispersion during convection-enhanced delivery in the brain.Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas.New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors.Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance.Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease Effect of needle insertion speed on tissue injury, stress, and backflow distribution for convection-enhanced delivery in the rat brain.Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.Neurocognitive functioning and quality of life in patients with recurrent malignant gliomas treated on a phase Ib trial evaluating topotecan by convection-enhanced delivery IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications.Predictive models for pressure-driven fluid infusions into brain parenchyma.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Canine model of convection-enhanced delivery of cetuximab-conjugated iron-oxide nanoparticles monitored with magnetic resonance imaging.Vascular distribution of glioblastoma multiforme at diagnosis Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors.Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus

P2860

Q26778701-613C4AAA-E127-4DCB-A801-54C5C2A07A6E Q26795601-E2A03652-B19D-435C-8495-7786FCB32C24 Q26825496-7C4D16B4-B995-49A0-BD53-41629BF4693E Q27004205-8CBFF5DE-8691-4326-BB90-C3B083F09FF2 Q27006099-D376B6DA-C392-4583-A469-B3E42D5D1516 Q27023618-7B355089-5785-4BCC-8A1E-07B96AEA1E52 Q28082016-02CFBBB0-2812-4161-A98E-5F13CE6C7783 Q28486200-0EC162DD-1C8A-43E8-B7F2-96B3DD0195CF Q28533650-16AB0C3C-CE67-4280-87DD-23550B2F5915 Q28535247-900A4EAE-B743-470F-B473-44C75A615343 Q28544645-5FA5683F-7C2C-419C-B2DE-46E59B4DAE0D Q30407443-C54DEE86-89CF-4460-9F14-78D396F93C74 Q30433568-AFD35751-7B99-4ECD-9FD8-EE4F60175C2F Q30433661-2F10D198-C7A2-4ED8-9087-B19F6B9A1217 Q30474781-53C5138F-AB41-4E4B-8B67-D39E87C67D09 Q30833619-87D04DA9-4393-4712-BDB9-237FACCDE6E7 Q31065446-8208BB5B-4B24-4622-9380-5158EB541600 Q33704489-5FB9AC39-C826-411C-ABEB-1913951E300D Q34030180-364DC441-A958-4668-8614-AAD9B4AE70BD Q34070650-44D64288-CEC2-40F8-99D5-ABF012E9EC77 Q34127138-014E7742-4E28-458B-BF23-DFE089367937 Q34579762-AC8DB6FC-AFAA-4C3B-AD04-998A25A978AB Q34785621-CF5D3316-A4A5-4AE5-9C3D-F76A220E2553 Q34789136-24641D6B-8B43-450E-9C10-F6440E9178DF Q34824767-F15A9F50-9506-4F50-B24D-6916E6C65FE8 Q34892014-9E6E1A2F-3670-4E42-BE21-11E654890F81 Q34954842-64FC5637-2D23-400C-BC2E-A65525AB8492 Q35023359-2CF86298-F60D-43D3-BD97-526818A5B8F2 Q35070535-88AC40A2-0E5D-4801-8DA5-9EBE424FE5D1 Q35086686-2B92856C-999A-4B67-9E5A-57B3B7F85BE7 Q35158961-14178FC0-58A5-4356-B3E9-73ECBF6B25D3 Q35159477-98EF3910-0F81-4838-8917-B014E731F710 Q35206202-80ED0CB2-2E64-4C24-8D12-3EE9FC82BE77 Q35626536-A36B2D90-9EC9-4A20-BD42-947D03653A45 Q35645959-DE8D57F4-F326-4414-B139-3113E89C1FE1 Q35999648-F4465D4F-F443-4861-BD14-0A3B7A17907E Q36322700-325B23F9-63A7-4AE0-A695-3AE743CB9606 Q36696392-A4828EAE-E438-45C7-8C52-734878155507 Q36971160-05D8D237-62C6-4AB4-B6E8-A9B2502B1A2D Q37026271-6CCA4B01-FA55-4778-A04C-149A3DE2A639

P2860

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

http://www.wikidata.org/entity/Q48374857

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@en

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@nl

type

label

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@en

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@nl

prefLabel

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@en

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@nl

P1433

Q48374857-29E1E197-476D-4F63-B137-5F7F36CBC250

P1476

Q48374857-C0C22F77-1BA4-48B0-B449-D54FF72F8ED6

P2093

Q48374857-042C3A1B-7A75-48DE-83A8-A81D9348813B

Q48374857-14EC83F9-9B73-4BA2-A13F-63B3933B0193

Q48374857-1F8B2463-887D-4136-8121-60620E5B8BB2

Q48374857-27763B37-51BB-44E6-91CC-876022AE9342

Q48374857-35A1CEAC-F4BA-4A2B-A7E2-B3C7BE21F060

Q48374857-4037DC72-3562-4B3B-8915-820332E0E0DC

Q48374857-41C4FBEA-EF9A-480E-919A-662DA4F620CB

Q48374857-47D84B9F-263B-4E82-A896-5DB951782BC7

Q48374857-809D6A4F-620C-4303-84EF-0BD3F27A8D06

Q48374857-8D40B6B0-866F-4553-96E3-FE17C6A308C1

P304

Q48374857-0AA80320-06F7-4FF3-97CE-EB03A53438A6

P31

Q48374857-419030D2-5C04-4C55-A205-40F0848911ED

P356

Q48374857-9A08461E-0C4F-4C98-A641-5BAD6911F2AA

P407

Q48374857-801FD389-117B-4B33-A6EC-E56339B4F8AD

P433

Q48374857-08825B9F-4EAD-469C-807F-B4D686E881E5

P478

Q48374857-C5A2DC08-3566-468B-9981-2CB2B93913B0

P50

Q48374857-4B0E2BF9-B026-4198-BEB3-F848D1231ADE

Q48374857-7067057C-6FAB-44C0-B517-7103D21149BA

Q48374857-734FC0FA-6F76-4311-BE47-19F22FEB9097

Q48374857-F7970AC3-7B9E-4563-BFA1-F86142B2283B

P577

Q48374857-3B67F21B-57FE-4C02-B3C1-DB8C08688AD0

P698

Q48374857-44188A6B-7EF3-4C6A-BF74-A64FC1E09612

P356

2009.11.JNS091052

P1433

Journal of Neurosurgery

P1476

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

@en

P2093

Christoph Pedain

http://www.w3.org/2001/XMLSchema#string

David Croteau

http://www.w3.org/2001/XMLSchema#string

Eva Wembacher-Schröder

http://www.w3.org/2001/XMLSchema#string

Gary Archer

http://www.w3.org/2001/XMLSchema#string

James E Herndon

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

M Inmaculada Rodríguez-Ponce

http://www.w3.org/2001/XMLSchema#string

Manfred Westphal

http://www.w3.org/2001/XMLSchema#string

Martin L Brady

http://www.w3.org/2001/XMLSchema#string

Michael A Vogelbaum

http://www.w3.org/2001/XMLSchema#string

P304

301-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3171/2009.11.JNS091052

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Henry Seth Friedman

David A Reardon

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20020841

http://www.w3.org/2001/XMLSchema#string